[Morphological and pharmacological-toxicological aspects of hyperoxia].
D000613:Aminobutyrates / Q000627:therapeutic use; D000818:Animals; D001274:Atmospheric Pressure; D001927:Brain Diseases / Q000139:chemically induced / Q000209:etiology; D003975:Diazepam / Q000627:therapeutic use; D005724:Ganglia; D006801:Humans; D008168:Lung / Q000032:analysis; D008171:Lung Diseases / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy; D009120:Muscle Cramp / Q000139:chemically induced; D010100:Oxygen / Q000009:adverse effects* / Q000032:analysis; D010313:Partial Pressure; D010634:Phenobarbital / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D011654:Pulmonary Edema / Q000209:etiology; D051381:Rats; D013997:Time Factors; D014293:Trimethadione / Q000627:therapeutic use; D014325:Tromethamine / Q000627:therapeutic use
D000613:Aminobutyrates; D014325:Tromethamine; D010672:Phenytoin; D003975:Diazepam; D014293:Trimethadione; D010100:Oxygen; D010634:Phenobarbital; D010646:Phentolamine
Morphologische und pharmakologisch-toxikologische Aspekte der Hyperoxie.